This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FDA Accepts Karuna's (KRTX) NDA Filing for Schizophrenia Drug
by Zacks Equity Research
If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. A final decision is expected in September 2024.
Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.
Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
by Zacks Equity Research
The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.
Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study
by Zacks Equity Research
Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
by Zacks Equity Research
The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.
3 Large Drug Stocks That Have Outperformed Industry YTD
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.
The Zacks Analyst Blog Highlights Gartner, The Progressive, InterContinental Hotels, Cboe Global Markets and Novo Nordisk
by Zacks Equity Research
Gartner, The Progressive, InterContinental Hotels, Cboe Global Markets and Novo Nordisk are included in this Analyst Blog.
5 Must-Buy Stocks at 52-Week High With More Upside for 2024
by Nalak Das
We have narrowed our search to five large-cap stocks with more upside for 2024. These are: IT, PGR, CBOE, IHG, NVO.
Beat the Market Like Zacks: UnitedHealth, Casey's, Cencora in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
4 Must-Buy Profitable Stocks Using Net Income Ratio
by Tirthankar Chakraborty
Lamb Weston (LW), e.l.f. Beauty (ELF), Novo Nordisk (NVO), and NVIDIA (NVDA) have been selected as the top picks with a high net income ratio.
The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce
by Zacks Equity Research
Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce are included in this Analyst Blog.
Here's Why Investors Should Hold Encompass Health (EHC) Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of an active expansion strategy and sufficient cash-generating abilities.
Top Stock Reports for Eli Lilly, Accenture & The TJX Companies
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Accenture plc (ACN) and The TJX Companies, Inc. (TJX).
Novo Nordisk (NVO) to Expand Manufacturing Site in France
by Zacks Equity Research
Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.
Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More
by Kinjel Shah
Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3 billion to expand an existing production site in France.
New Strong Buy Stocks for November 24th
by Zacks Equity Research
NVO, PAY, AIZ, MOD and LEU have been added to the Zacks Rank #1 (Strong Buy) List on November 24, 2023.
Eli Lilly (LLY) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.
The Zacks Analyst Blog Highlights Novo Nordisk Bank of America, Netflix, Johnson & Johnson and TotalEnergies
by Zacks Equity Research
Novo Nordisk, Bank of America, Netflix, Johnson & Johnson and TotalEnergies are part of the Zacks top Analyst Blog.
Merck (MRK) to Acquire Private Neuroscience Company for $610M
by Zacks Equity Research
Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.
Here's How Much You'd Have If You Invested $1000 in Novo Nordisk a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Top Analyst Reports for Novo Nordisk, Bank of America & Netflix
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Bank of America Corporation (BAC) and Netflix, Inc. (NFLX).
J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant
by Zacks Equity Research
J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib).
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand
by Zacks Equity Research
Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.